



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Earl Ray Tomblin
Governor

Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Karen L. Bowling
Cabinet Secretary

Pharmaceutical and Therapeutics Committee
October 23, 2013

Location: Charleston Civic Center
Time: 9:00 AM – 5:00 PM
200 Civic Center Drive
Charleston, WV 25301-2016
(304) 558-1700

AGENDA

Therapeutic Class List on Page 2

- I. Call to Order
- II. Welcome and Introductions
- III. Housekeeping Items/Updates
 - a. Approval of the April 24, 2013 Minutes
 - b. Explanation of Extraction Process
 - c. PDL Compliance/Generic Percent Report Updates
 - d. Review of new business rule for PDL additions
 - e. Method of communication to P&T members
- IV. MMA Presents Summary of Recommended PDL Changes
- V. Chairman Calls for First Round of Extractions
- VI. Public Comments (Agenda classes only - limit three minutes per product)
- VII. Chairman Calls for Second Round of Extractions
- VIII. Motion for All Non-Extracted Categories to be Approved as Proposed
- IX. Executive Session
- X. Lunch Break, approximately 1:00 PM-2:00 PM
- XI. Extracted Therapeutic Category Reviews/Committee Recommendations
- XII. Next Meeting – January 29, 2014, 2PM – 5PM, Diamond Building
- XIII. Other Business
- XIV. Adjournment

Therapeutic Classes to be Reviewed: October 23, 2013

(Reviewed in PDL order)

1. Acne Agents, Topical
2. Alzheimer's Agents
3. Analgesics, Narcotic – Short-Acting (Nonparenteral)
4. Analgesics, Narcotic – Long Acting (Non-Parenteral)
5. Androgenic Agents
6. Anesthetics, Topical
7. Angiotensin Modulators
8. Antianginal & Anti-Ischemic
9. Antibiotics, GI
10. Antibiotics, Inhaled
11. Antibiotics, Topical
12. Antibiotics, Vaginal
13. Anticoagulants
14. Anticonvulsants
15. Antidepressants, Other
16. Antidepressants, SSRIs
17. Antiemetics
18. Antifungals, Oral
19. Antifungals, Topical
20. Antihistamines, Minimally Sedating
21. Antihypertensives, Sympatholytics
22. Antihyperuricemics
23. Antimigraine Agents, Triptans
24. Antiparasitics, Topical
25. Antiparkinson's Agents
26. Antipsoriatics, Topical
27. Antipsychotics, Atypical
28. Antivirals, Oral
29. Antivirals, Topical
30. Beta Blockers
31. Bladder Relaxants
32. Bone Resorption Suppression and Related Agents
33. BPH Treatments
34. Bronchodilators, Beta Agonist
35. Calcium Channel Blockers
36. Cephalosporins and Related Antibiotics
37. Colony Stimulating Factors
38. COPD Agents
39. Cytokine and CAM Antagonists
40. Epinephrine, Self-Injected
41. Erythropoiesis Stimulating Proteins
42. Fluoroquinolones, Oral
43. Glucocorticoids, Inhaled
44. Growth Hormone
45. H. Pylori Treatment
46. Hepatitis B Agents
47. Hepatitis C Agents
48. Hyperparathyroid Agents
49. Hypoglycemics, Incretins
50. Hypoglycemics, Insulins
51. Hypoglycemics, Meglitinides
52. Hypoglycemics, SGLT2
53. Hypoglycemics, TZDs
54. Immune Globulins, IV
55. Immunomodulators, Atopic Dermatitis
56. Immunomodulators, Topical & Genital Warts Agents
57. Immunosuppressives, Oral
58. Intermittent Claudication
59. Intranasal Rhinitis Agents
60. Leukotriene Modifiers
61. Lipotropics, Other (Non-Statins)
62. Lipotropics, Statins
63. Macrolides/Ketolides (Oral)
64. Multiple Sclerosis Agents
65. Neuropathic Pain
66. NSAIDs
67. Ophthalmic Antibiotics
68. Ophthalmic Antibiotic/Steroid Combinations
69. Ophthalmics for Allergic Conjunctivitis
70. Ophthalmics, Anti-Inflammatories
71. Ophthalmics, Glaucoma Agents
72. Opiate Dependence Treatments
73. Otic Antibiotics
74. PAH Agents, Endothelin Receptor Antagonists
75. PAH Agents, PDE5s
76. PAH Agents, Prostacyclins
77. Pancreatic Enzymes
78. Phosphate Binders
79. Platelet Aggregation Inhibitors
80. Progestins for Cachexia
81. Proton Pump Inhibitors
82. Sedative Hypnotics
83. Skeletal Muscle Relaxants
84. Steroids, Topical

Note: P&T review will include all products available by 60 days prior to the meeting date (based on criteria approved by BMS).

Therapeutic Classes to be Reviewed: October 23, 2013

(Reviewed in PDL order)

- 85. Stimulants and Related Agents
- 86. Tetracyclines
- 87. Ulcerative Colitis Agents
- 88. Vasodilators, Coronary (SL NTG)

Note: P&T review will include all products available by 60 days prior to the meeting date
(based on criteria approved by BMS).
